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Research Round Up- Antimicrobial Prescribing in SARS-CoV-2 
 
Introduction 
The last research round up provided you with a review some disparate prescribing issues that have 
arisen and been reviewed due to the current pandemic. One of those articles reviewed was the 
trend in out of hour antibiotic prescribing before and during the COVID-19 pandemic. This month we 
will follow up with a review of antimicrobial prescribing practices in patients being treated for SARS-
CoV-2 either the use of these for COVID-19 itself or for detected secondary infection. 
 
Antimicrobial Prescribing Practices at A Tertiary-Care Centre in Patients Diagnosed With COVID-19 
Across the Continuum of Care 
In this article from July 2020 published by Cambridge University Press we start to see some early 
evidence looking at the rate and spectrum of antibiotic prescribing being collected in a single centre 
study. This study was a retrospective review of data of local patients diagnosed with COVID-19 at a 
large, academic, tertiary-care treatment centre and included all inpatient, emergency department 
(ED), or outpatient encounters of patients with confirmed COVID-19 infection to analyse the 
prevalence, number of agents, spectrum of activity, and duration of antimicrobial therapy. Only 
adult patients’ records were reviewed and those who had had covid-19 confirmed by PCR test. The 
records reviewed spanned the period between 1st March and 29th April 2020 leading to 346 patient 
records meeting inclusion criteria to be studied. Across the entire cohort, 10% of patients received 
antimicrobial therapy for a mean duration of 5.7 days. Antimicrobials were administered in 59% of 
all inpatients with rates of 29%, 47%, and 87% for mild, moderate, and severe cases, 
respectively. Prescribing rate, spectrum, and duration appeared to increase with disease severity in 






Antibiotic Prescribing in Patients With COVID-19: Rapid Review and Meta-Analysis 
This in press rapid review publication using a modified Cochrane review methodology, sought to 
elucidate the prevalence of antibiotic prescribing during patient infection with COVID-19. Numerous 
databases were searched to find studies fitting inclusion criteria which included laboratory-
confirmed SARS-CoV-2 infection, across all healthcare settings and age groups and considered cohort 
studies, case series and randomised control trials. The authors excluded reviews, editorials, letters 
and case studies. They also excluded any larger studies where the number and percentage of 
infected patients on antibiotic therapy was not reported. The authors suggest that despite frequent 
antibiotic prescribing to patients with COVID-19, the prevalence of bacterial co-infection and 
secondary infection in patients hospitalized with COVID-19 is relatively low at 3.5% and 14.3%, 
respectively according to their review of the available literature. The main outcome of interest was 
proportion of COVID-19 patients prescribed an antibiotic, stratified by geographical region, severity 
of illness and age. 
7469 studies were screened and of those, 154 met their inclusion criteria. Prescribing data and 
antibiotic data were available from 30 623 patients across the 154 studies reviewed. The authors 
found that the prevalence of antibiotic prescribing across the papers included was 74.6% On 
subjecting the data to univariable meta-regression, antibiotic prescribing was lower in children 
(prescribing prevalence odds ratio (OR) 0.10, 95% CI 0.03e0.33) compared with adults. They also 
discuss the fact that antibiotic prescribing was seen to be higher with increasing patient age (OR 1.45 
per 10 year increase, 95% CI 1.18e1.77) and also reported a higher incidence of prescribing  with 
increasing proportion of patients requiring mechanical ventilation (OR 1.33 per 10% increase, 95% CI 
1.15e1.54). Their findings revealed that the estimated bacterial co-infection was 8.6% (95% CI 
4.7e15.2%) from 31 studies.  
The authors concluded from these findings that up to 75%  of patients with COVID-19 are prescribed 
antibiotics, but that prescribing of the antibiotic therapy is not synchronised with but is in fact  
significantly higher than the estimated prevalence of bacterial co-infection. Unnecessary antibiotic 
use is likely to be high in patients with COVID-19, and further studies on the rationale for and 




A Point Prevalence Survey to Assess Antibiotic Prescribing in Patients Hospitalized with Confirmed 
and Suspected Coronavirus Disease 2019 (COVID-19) 
 
This point prevalence survey of antibiotic use was conducted on 22 April 2020, at 08:00 h in patients 
with suspected and confirmed COVID-19 at the National Centre for Infectious Diseases and Tan Tock 
Seng Hospital in Singapore. The aim of this was to confirm or refute the hypothesis that increased 
antibiotic use during the pandemic could result in an increase in antimicrobial resistance. The 
authors discuss early studies which report high antibiotic use in COVID-19 patients and the concerns 
of clinicians around this prescribing trend. They chose to use a point prevalence survey as it is a 
quick and easy tool that can be used for many aspects of healthcare intervention. The aim was to 
use the data to inform antimicrobial stewardship activity and policy. 577 patients met the inclusion 
criteria of being on systemic antibiotics and were included in the study for screening.  
The authors report that thirty-six (6.2%) patients were on antibiotics and which were started at 
median of 7 days (inter-quartile rate (IQR), 4, 11) from symptom onset. Fifty-one antibiotics were 
prescribed in these patients. Overall, co-amoxiclav (26/51, 51.0%) was the most often prescribed 
antibiotic. Thirty-one out of 51 (60.8%) antibiotic prescriptions were appropriate. Among 20 
inappropriate prescriptions, 18 (90.0%) were initiated in patients with low likelihood of bacterial 
infections. The low antibiotic prevalence was likely to be a result of fewer severely ill cases, with only 
1.9% admitted to ICU. Antibiotics were typically started in the second week of illness during the 
hyperinflammatory phase, making the differentiation between viral and secondary bacterial 
infection challenging. Antibiotic prescriptions were more appropriate when reviewed by infectious 
diseases physicians (13/31 [41.9%] versus 2/20 [10.0%], p = 0.015), and if reasons for use were 
stated in notes (31/31 [100.0%] versus 16/20 [80.0%], p = 0.019). 
The authors conclude that although there was allow prevalence of antibiotic use in both confirmed 
and suspected infection with COVID-19, there was a significant percentage of inappropriate 
antimicrobial prescription in patients where a secondary bacterial infection was unlikely. This 






What is clear is that the COVID-19 pandemic continues to impact on many aspects of healthcare 
provision and this month’s focus on antimicrobial prescribing and stewardship shows the variety and 
progression of evidence on such an area of healthcare practice. Like many emerging areas of 
research around the pandemic effects it is likely that more evidence on this will continue to be 
published over the next few months and even years. What is clear from the evidence presented 
above is that antibiotic therapy is of dubious benefit in treating COVID-19 infection but may be more 
useful where secondary bacterial infections are detected and confirmed. It also shows that even in 
the time of a global pandemic, antibiotic stewardship remains a vital role for the prescriber and it is 
important to continue to prescribe antibiotic therapy in a clinically appropriate manner.  
 
